Kenneth E. Hung
Pfizer (United States)(US)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Inflammatory Bowel Disease, Cancer Research and Treatments, Melanoma and MAPK Pathways, Cancer Cells and Metastasis
Most-Cited Works
- → The Central Role of CD4+ T Cells in the Antitumor Immune Response(1998)1,336 cited
- → Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth(2012)1,293 cited
- → EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib(2012)1,018 cited
- → Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture(2014)447 cited
- → Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models(2012)378 cited
- → Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment(2010)199 cited
- → In vivo wide-area cellular imaging by side-view endomicroscopy(2010)142 cited
- → The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer(2011)139 cited
- → mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1(2013)127 cited
- → Detection of Proximal Adenomatous Polyps With Screening Sigmoidoscopy(2003)112 cited